Scientific Reports (Nov 2021)
Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome
- Sara Remuzgo-Martínez,
- Belén Atienza-Mateo,
- J. Gonzalo Ocejo-Vinyals,
- Fernanda Genre,
- Verónica Pulito-Cueto,
- Víctor M. Mora-Cuesta,
- David Iturbe-Fernández,
- Leticia Lera-Gómez,
- Raquel Pérez-Fernández,
- Diana Prieto-Peña,
- Juan Irure,
- Fredeswinda Romero-Bueno,
- Olga Sanchez-Pernaute,
- Rodrigo Alonso-Moralejo,
- Laura Nuño,
- Gema Bonilla,
- Esther F. Vicente-Rabaneda,
- Ignacio Grafia,
- Sergio Prieto-González,
- Javier Narvaez,
- Ernesto Trallero-Araguas,
- Albert Selva-O’Callaghan,
- Spanish Biomarkers of Antisynthetase Syndrome Consortium,
- Spanish Biomarkers of Interstitial Lung Disease Consortium,
- Oreste Gualillo,
- Lorenzo Cavagna,
- José M. Cifrián,
- Elisabetta A. Renzoni,
- Santos Castañeda,
- Raquel López-Mejías,
- Miguel A. González-Gay
Affiliations
- Sara Remuzgo-Martínez
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Belén Atienza-Mateo
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- J. Gonzalo Ocejo-Vinyals
- Department of Immunology, Hospital Universitario Marqués de Valdecilla
- Fernanda Genre
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Verónica Pulito-Cueto
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Víctor M. Mora-Cuesta
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- David Iturbe-Fernández
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Leticia Lera-Gómez
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Raquel Pérez-Fernández
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Diana Prieto-Peña
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Juan Irure
- Department of Immunology, Hospital Universitario Marqués de Valdecilla
- Fredeswinda Romero-Bueno
- Rheumatology Department, Hospital Universitario Fundación Jiménez Díaz
- Olga Sanchez-Pernaute
- Rheumatology Department, Hospital Universitario Fundación Jiménez Díaz
- Rodrigo Alonso-Moralejo
- Lung Transplant Unit, Hospital Universitario 12 de Octubre
- Laura Nuño
- Rheumatology Department, Hospital Universitario La Paz
- Gema Bonilla
- Rheumatology Department, Hospital Universitario La Paz
- Esther F. Vicente-Rabaneda
- Rheumatology Department, Hospital de la Princesa, IIS-Princesa
- Ignacio Grafia
- Department of Autoimmune Diseases, Hospital Clínico de Barcelona, Universidad de Barcelona
- Sergio Prieto-González
- Department of Autoimmune Diseases, Hospital Clínico de Barcelona, Universidad de Barcelona
- Javier Narvaez
- Rheumatology Department, Hospital Universitario de Bellvitge
- Ernesto Trallero-Araguas
- Rheumatology Unit, Hospital Universitario Vall d’Hebron
- Albert Selva-O’Callaghan
- Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d’Hebron
- Spanish Biomarkers of Antisynthetase Syndrome Consortium
- Spanish Biomarkers of Interstitial Lung Disease Consortium
- Oreste Gualillo
- SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Hospital Clínico Universitario de Santiago
- Lorenzo Cavagna
- Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation
- José M. Cifrián
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Elisabetta A. Renzoni
- Interstitial Lung Disease Unit, Royal Brompton Hospital, Imperial College London
- Santos Castañeda
- Rheumatology Department, Hospital de la Princesa, IIS-Princesa
- Raquel López-Mejías
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- Miguel A. González-Gay
- Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Diseases of the Musculoskeletal System, IDIVAL
- DOI
- https://doi.org/10.1038/s41598-021-01992-y
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 8
Abstract
Abstract Mucin 1/Krebs von den Lungen-6 (KL-6) is proposed as a serum biomarker of several interstitial lung diseases (ILDs), including connective tissue disorders associated with ILD. However, it has not been studied in a large cohort of Caucasian antisynthetase syndrome (ASSD) patients. Consequently, we assessed the role of MUC1 rs4072037 and serum KL-6 levels as a potential biomarker of ASSD susceptibility and for the differential diagnosis between patients with ILD associated with ASSD (ASSD-ILD +) and idiopathic pulmonary fibrosis (IPF). 168 ASSD patients (149 ASSD-ILD +), 174 IPF patients and 523 healthy controls were genotyped for MUC1 rs4072037 T > C. Serum KL-6 levels were determined in a subgroup of individuals. A significant increase of MUC1 rs4072037 CC genotype and C allele frequencies was observed in ASSD patients compared to healthy controls. Likewise, MUC1 rs4072037 TC and CC genotypes and C allele frequencies were significantly different between ASSD-ILD+ and IPF patients. Additionally, serum KL-6 levels were significantly higher in ASSD patients compared to healthy controls. Nevertheless, no differences in serum KL-6 levels were found between ASSD-ILD+ and IPF patients. Our results suggest that the presence of MUC1 rs4072037 C allele increases the risk of ASSD and it could be a useful genetic biomarker for the differential diagnosis between ASSD-ILD+ and IPF patients.